title: The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
abstract: OBJECTIVE
  To assess the long-term efficacy and safety of conventional radiotherapy (RT) in the control of acromegaly according to recent stringent criteria of cure.
  
  
  METHODS
  A retrospective longitudinal study.
  
  
  METHODS
  Forty-seven patients with active acromegaly were treated with conventional RT between 1982 and 1994. All patients were first operated on and successively irradiated at a dose of 45-50 Gy in 25-28 fractions for persistent (n = 40) or recurrent (n = 7) disease.
  
  
  METHODS
  Long-term GH/IGF-I secretion and local tumour control were evaluated regularly, and possible side-effects were searched for systematically, especially in terms of secondary endocrine dysfunction. Biochemical cure of acromegaly was defined by glucose-suppressed plasma GH levels below 1 microg/l during an oral glucose tolerance test (OGTT) and normal age-corrected IGF-I values.
  
  
  RESULTS
  The 5-, 10- and 15-year overall survival rates were 98%, 95% and 93%, respectively. Suppression of GH during OGTT was seen in 9% of patients at 2 years, 29% at 5 years, 52% at 10 years, and 77% at 15 years. Age-corrected IGF-I levels were normal in 8% of patients 2 years after RT, and this proportion increased to 23%, 42% and 61% after 5, 10 and 15 years, respectively. Normalization of GH/IGF-I mainly depended on pre-RT levels. Local tumour control was 95% at 5, 10 and 15 years after treatment. Late toxicity was mainly represented by progressive hypopituitarism, which was present in 33% of patients at baseline and increased to 57%, 78% and in 85% of patients at 5 10 and 15 years after RT, respectively.
  
  
  CONCLUSIONS
  Conventional RT is effective in the long-term control of GH-secreting pituitary adenomas, although with a high prevalence of progressive hypopituitarism. At present, it remains a suitable option in acromegalic patients uncontrolled by surgery or medical therapy.
authors.affiliation: Neurological Sciences, IRCCS-NEUROMED, Pozzilli, Italy. giuseppeminniti@libero.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Minniti
authors.forename: Marie-Lise
authors.initials: ML
authors.lastname: Jaffrain-Rea
authors.forename: Mattia
authors.initials: M
authors.lastname: Osti
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Esposito
authors.forename: Antonio
authors.initials: A
authors.lastname: Santoro
authors.forename: Francesca
authors.initials: F
authors.lastname: Solda
authors.forename: Patrizia
authors.initials: P
authors.lastname: Gargiulo
authors.forename: Guido
authors.initials: G
authors.lastname: Tamburrano
authors.forename: Riccardo Maurizi
authors.initials: RM
authors.lastname: Enrici
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000401:mortality / Q000532:radiotherapy*; D000236:Adenoma / Q000378:metabolism* / Q000401:mortality / Q000532:radiotherapy*; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D005951:Glucose Tolerance Test; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000532:radiotherapy*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone